Dauricine是一种从Menispermum dauricum DC.中提取的具有抗癌活性的生物碱。
Cas No.:524-17-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Dauricine is a bioactive alkaloid with anticancer properties extracted from Menispermum dauricum DC. Dauricine inhibits tumor cell proliferation and induces apoptosis by suppressing signaling pathways such as Hedgehog, PI3K/Akt, and Src/STAT3[1-2]. Dauricine is applicable for research in various cancers and Alzheimer's disease[3-4].
In vitro, PC9-OR and H1975-OR osimertinib-resistant lung cancer cell lines were co-treated with Dauricine (0-100μM) and osimertinib. Dauricine induced ferroptosis in the cells, significantly inhibiting their viability[5]. A549, H1299, A427, and LLC lung adenocarcinoma cells were treated with Dauricine (5–20μM) for 24–48 hours. Dauricine significantly inhibited cell proliferation and migration, induced cell cycle arrest at the G0/G1 phase, increased intracellular reactive oxygen species (ROS) levels, downregulated Nrf2 expression, and ultimately triggered apoptosis[6].
In vivo, nude mice bearing BxPC-3 pancreatic cancer xenografts were treated with daily intraperitoneal injections of Dauricine (6mg/kg and 12mg/kg) for 21 days. Dauricine significantly inhibited tumor growth without markedly affecting the spleen index[7]. Ten-week-old female C57BL/6J mice were treated with intraperitoneal injections of Dauricine (2.5mg/kg; every two days) in combination with LPS (5mg/kg; once a week) for 3 weeks. Dauricine significantly alleviated LPS-induced inflammatory bone loss[8].
References:
[1] Chen KQ, Wang SZ, Lei HB, et al. Dauricine: Review of Pharmacological Activity. Drug Des Devel Ther. 2024 Sep 27;18:4371-4385.
[2] Li L, Dai S, Liu JY, et al. Antagonistic Effect and In Vitro Activity of Dauricine on Glucagon Receptor. J Nat Prod. 2022 Aug 26;85(8):2035-2043.
[3] Zhang X, Wang T, Miao Y, et al. Dauricine exhibits anti-inflammatory property against acute ulcerative colitis via the regulation of NF-κB pathway. Cell Biochem Funct. 2023 Aug;41(6):713-721.
[4] Wang L, Pu Z, Li M, et al. Antioxidative and antiapoptosis: Neuroprotective effects of dauricine in Alzheimer's disease models. Life Sci. 2020 Feb 15;243:117237.
[5] Men B, Chen Z, Ge H, et al. Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1. Cancer Sci. 2025 Aug;116(8):2256-2269.
[6] Yousuf W, Siddiqui NZ, Ali P, et al. Dauricine Impedes the Tumorigenesis of Lung Adenocarcinoma by Regulating Nrf2 and Reactive Oxygen Species. Cells. 2025 May 12;14(10):698.
[7] Zhang YB, Fei HX, Guo J, et al. Dauricine suppresses the growth of pancreatic cancer in vivo by modulating the Hedgehog signaling pathway. Oncol Lett. 2019 Nov;18(5):4403-4414.
[8] Park HJ, Gholam Zadeh M, et al. Dauricine Protects from LPS-Induced Bone Loss via the ROS/PP2A/NF-κB Axis in Osteoclasts. Antioxidants (Basel). 2020 Jul 6;9(7):588.
Dauricine是一种从Menispermum dauricum DC.中提取的具有抗癌活性的生物碱。Dauricine可通过抑制Hedgehog、PI3K/Akt和Src/STAT3等信号通路来抑制肿瘤细胞增殖并诱导细胞凋亡[1-2]。Dauricine可用于多种癌症以及阿尔茨海默病的相关研究[3-4]。
在体外，Dauricine（0-100μM）与Osimertinib联合处理PC9-OR和H1975-OR奥希替尼耐药肺癌细胞系。Dauricine可诱导细胞发生铁死亡，显著抑制细胞活性[5]。Dauricine（5–20μM）处理A549、H1299、A427和LLC肺腺癌细胞24–48小时。Dauricine显著抑制细胞增殖与迁移，诱导G0/G1期细胞周期阻滞，同时增加细胞内活性氧（ROS）水平并下调Nrf2表达，最终触发细胞凋亡[6]。
在体内，Dauricine（6mg/kg及12mg/kg）每天腹腔注射，连续处理21天，用于BxPC-3胰腺癌异种移植瘤模型裸鼠。Dauricine显著抑制了肿瘤生长，且未对脾脏指数产生显著影响[7]。Dauricine（2.5mg/kg）每两天一次腹腔注射，联合LPS（5mg/kg）每周一次腹腔注射，处理10周龄C57BL/6J雌性小鼠3周。Dauricine显著减轻了由LPS诱导的炎症性骨丢失[8]。
| Cell experiment [1]: | |
Cell lines | A549, H1299, A427, and Lewis Lung Carcinoma (LLC) cells (lung adenocarcinoma cell lines) |
Preparation Method | A549 and H1299 cells were maintained in RPMI-1640 medium, A427 cells in Modified Eagles Medium (MEM), and LLC cells in Dulbecco's Modified Eagles Medium (DMEM), all supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37°C, 5% CO₂. Cells were treated with Dauricine (5–20μM) for 24-48 hours |
Reaction Conditions | 5–20μM; 24-48 hours. |
Applications | Dauricine significantly inhibited the proliferation and migration of lung adenocarcinoma cells, induced cell cycle arrest at the G0/G1 phase, and markedly increased intracellular reactive oxygen species (ROS) levels. Dauricine also led to the downregulation of the redox regulator Nrf2 and altered the expression of apoptosis-related markers (decreased Bcl-2, increased BAX and cleaved Caspase 3). |
| Animal experiment [2]: | |
Animal models | 10-week-old female C57BL/6J mice |
Preparation Method | Mice were randomly assigned to four groups and treated via intraperitoneal injection for 3 weeks. Groups received: (1) vehicle control (PBS); (2) vehicle with Dauricine (2.5mg/kg, once every two days); (3) LPS (5mg/kg, once a week); (4) LPS with Dauricine. |
Dosage form | 2.5mg/kg; i.p.; once every two days for 3 weeks. |
Applications | Co-treatment with Dauricine significantly prevented LPS-induced bone loss, as evidenced by increased bone mineral density (BMD), bone volume (BV/TV), and trabecular thickness (Tb.Th), and decreased trabecular separation (Tb.Sp). Dauricine also reduced the number of osteoclasts (OC.N/BS), lowered serum levels of the bone resorption marker CTX-1, the inflammatory marker MCP-1, and reactive oxygen species (ROS) elevated by LPS. Dauricine alone did not induce significant differences compared to the vehicle control. |
References: | |
| Cas No. | 524-17-4 | SDF | |
| 别名 | 蝙蝠葛碱 | ||
| Canonical SMILES | OC1=CC=C(C[C@H]2N(C)CCC3=C2C=C(OC)C(OC)=C3)C=C1OC4=CC=C(C[C@H]5N(C)CCC6=C5C=C(OC)C(OC)=C6)C=C4 | ||
| 分子式 | C38H44N2O6 | 分子量 | 624.77 |
| 溶解度 | DMSO : 100 mg/mL (160.06 mM; Need ultrasonic) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6006 mL | 8.0029 mL | 16.0059 mL |
| 5 mM | 320.1 μL | 1.6006 mL | 3.2012 mL |
| 10 mM | 160.1 μL | 800.3 μL | 1.6006 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet